[go: up one dir, main page]

MXPA02005639A - Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. - Google Patents

Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.

Info

Publication number
MXPA02005639A
MXPA02005639A MXPA02005639A MXPA02005639A MXPA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A MX PA02005639 A MXPA02005639 A MX PA02005639A
Authority
MX
Mexico
Prior art keywords
human papillomavirus
peptide
nucleic acid
immune responses
cellular immune
Prior art date
Application number
MXPA02005639A
Other languages
English (en)
Inventor
Howard M Grey
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of MXPA02005639A publication Critical patent/MXPA02005639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invencion utiliza nuestros conocimientos de los mecanismos a traves de los cuales un antigeno es reconocido por celulas T para identificar y preparar epitopos de virus de papiloma humano (HPV) y para desarrollar vacunas basadas en epitopos dirigidas contra HPV. Mas especificamente, esta solicitud comunica nuestro descubrimiento de composiciones farmaceuticas y metodos de uso para la prevencion y el tratamiento de infeccion por HPV.
MXPA02005639A 1999-12-10 2000-12-11 Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. MXPA02005639A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17270599P 1999-12-10 1999-12-10
US09/641,528 US7026443B1 (en) 1999-12-10 2000-08-15 Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
PCT/US2000/033549 WO2001041799A1 (en) 1999-12-10 2000-12-11 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

Publications (1)

Publication Number Publication Date
MXPA02005639A true MXPA02005639A (es) 2004-09-10

Family

ID=26868370

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005639A MXPA02005639A (es) 1999-12-10 2000-12-11 Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.

Country Status (7)

Country Link
US (4) US7026443B1 (es)
EP (1) EP1246644A4 (es)
JP (1) JP2004512814A (es)
AU (3) AU2258201A (es)
CA (1) CA2393960C (es)
MX (1) MXPA02005639A (es)
WO (1) WO2001041799A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7842480B2 (en) * 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
EP1624890B1 (en) * 2003-01-24 2011-07-13 University Of Massachusetts Medical Center Identification of vaccinia virus dominant t cell epitopes
US8067535B2 (en) * 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
WO2005012528A1 (en) * 2003-08-01 2005-02-10 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences A method of preparing epitopes chimeric gene vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
US20070014810A1 (en) * 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US7517446B2 (en) * 2004-04-28 2009-04-14 Headwaters Heavy Oil, Llc Fixed bed hydroprocessing methods and systems and methods for upgrading an existing fixed bed system
US10941353B2 (en) 2004-04-28 2021-03-09 Hydrocarbon Technology & Innovation, Llc Methods and mixing systems for introducing catalyst precursor into heavy oil feedstock
KR101493631B1 (ko) 2004-04-28 2015-02-13 헤드워터스 헤비 오일, 엘엘씨 에뷸레이트 베드 하이드로프로세싱 방법 및 시스템 및 기존의 에뷸레이트 베드 시스템을 개량하는 방법
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
EP1877087B1 (en) * 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US20070218080A1 (en) * 2006-03-14 2007-09-20 Mackay Memorial Hospital Peptide antigen of human papillomavirus type 16 and application thereof
JP2009544333A (ja) * 2006-07-28 2009-12-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
WO2008145685A1 (en) * 2007-05-31 2008-12-04 Genimmune N.V. Hpv polyepitope constructs and uses thereof
US20110097332A1 (en) * 2007-08-06 2011-04-28 Martina Buck Composition and Method of Use for HCV Immunization
JP5731198B2 (ja) 2007-09-27 2015-06-10 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． インビボでのポリヌクレオチドの送達のための連続疎水相を含む担体におけるリポソームの使用
US8652482B2 (en) * 2007-10-03 2014-02-18 The Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
WO2009059225A2 (en) 2007-11-02 2009-05-07 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
US9096681B2 (en) 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
CA2731444A1 (en) * 2008-09-02 2010-03-11 Antigen Express, Inc. Human papillomavirus / li-key hybrids and methods of use
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
EP2536758B1 (en) * 2010-02-16 2019-01-02 Österreichische Akademie der Wissenschaften Anti-hpv e7 antibodies
US20120045413A1 (en) * 2010-04-09 2012-02-23 Mayumi Nakagawa Human papilloma virus peptide-specific T-cell response for treatment of warts
TWI507413B (zh) * 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
US8663964B2 (en) * 2011-07-20 2014-03-04 Tamir Biotechnology, Inc. Methods of treating human papillomavirus
US9790440B2 (en) 2011-09-23 2017-10-17 Headwaters Technology Innovation Group, Inc. Methods for increasing catalyst concentration in heavy oil and/or coal resid hydrocracker
ES2402286B1 (es) * 2011-09-29 2014-03-04 Universidad De Valladolid Péptido inmunogénico del gluten y sus aplicaciones.
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
US8715681B2 (en) * 2012-02-02 2014-05-06 Hengsun Pharmaceutical Technology Co. Ltd. Minimal motifs of linear B-cell epitopes in L1 protein from human papillomavirus type 58 and their applications
JP6404213B2 (ja) * 2012-07-05 2018-10-10 グワンジュ インスティテュート オブ サイエンス アンド テクノロジー ホスホランバンのプロテインホスファターゼ１媒介の脱リン酸化抑制用デコイペプチド｛ＤｅｃｏｙＰｅｐｔｉｄｅｓＩｎｈｉｂｉｔｉｎｇＰｒｏｔｅｉｎＰｈｏｓｐｈａｔａｓｅ１−ＭｅｄｉａｔｅｄＤｅｐｈｏｓｐｈｏｒｙｌａｔｉｏｎｏｆＰｈｏｓｐｈｏｌａｍｂａｎ｝
WO2014010229A1 (en) 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
US9644157B2 (en) 2012-07-30 2017-05-09 Headwaters Heavy Oil, Llc Methods and systems for upgrading heavy oil using catalytic hydrocracking and thermal coking
EP3919069A1 (en) 2012-11-05 2021-12-08 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
CN104004067B (zh) * 2013-02-22 2017-09-01 艾托金生物医药（苏州）有限公司 用于检测抗人乳头瘤病毒抗体的抗原及相关免疫检测试剂盒
CN110592133A (zh) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
EP2883550A1 (en) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
KR101677940B1 (ko) * 2014-07-18 2016-11-21 연세대학교 산학협력단 인유두종바이러스 e7 절단된 펩타이드의 자궁경부암 진단 및 치료 용도
KR101680567B1 (ko) 2014-07-09 2016-11-29 연세대학교 산학협력단 인유두종바이러스 펩타이드의 자궁경부암 진단 및 치료 용도
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US20180043008A1 (en) * 2015-02-26 2018-02-15 Bioventures, Llc Recall antigen for promoting t-helper type 1 response
ES2790725T3 (es) * 2015-03-16 2020-10-29 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Procedimiento de detección de nuevos epítopos de células T inmunogénicas y aislamiento de nuevos receptores de células T específicas de antígeno mediante una biblioteca de células de MHC
MX2017016368A (es) 2015-06-15 2018-04-24 Tamir Biotechnology Inc Farmaceuticos para tratamiento de infecciones virales de los ojos.
US11414607B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor with increased production rate of converted products
US11414608B2 (en) 2015-09-22 2022-08-16 Hydrocarbon Technology & Innovation, Llc Upgraded ebullated bed reactor used with opportunity feedstocks
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种宫颈癌相关的热休克蛋白复合物及其应用
US11421164B2 (en) 2016-06-08 2022-08-23 Hydrocarbon Technology & Innovation, Llc Dual catalyst system for ebullated bed upgrading to produce improved quality vacuum residue product
WO2018039203A1 (en) 2016-08-23 2018-03-01 Oncopep, Inc. Peptide vaccines and durvalumab for treating multiple myeloma
US20190209669A1 (en) 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
US11732203B2 (en) 2017-03-02 2023-08-22 Hydrocarbon Technology & Innovation, Llc Ebullated bed reactor upgraded to produce sediment that causes less equipment fouling
KR102505534B1 (ko) 2017-03-02 2023-03-02 하이드로카본 테크놀로지 앤 이노베이션, 엘엘씨 오염 침전물이 적은 업그레이드된 에뷸레이티드 베드 반응기
EP3606550A2 (en) * 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
US11517591B2 (en) 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
WO2019083960A1 (en) 2017-10-24 2019-05-02 Oncopep, Inc. PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
AU2018353984A1 (en) 2017-10-24 2020-05-07 Oncopep, Inc. Peptide vaccines and pembrolizumab for treating breast cancer
US20210046114A1 (en) * 2018-01-24 2021-02-18 The Council Of The Queensland Institute Of Medical Research Hpv immunotherapy
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CA3057131C (en) 2018-10-17 2024-04-23 Hydrocarbon Technology And Innovation, Llc Upgraded ebullated bed reactor with no recycle buildup of asphaltenes in vacuum bottoms
CN109517033B (zh) * 2018-10-31 2021-02-05 深圳凯联健康生物科技有限公司 活性肽、重组载体、重组细胞、抗炎组合物及其制备方法和应用
CN111440811A (zh) * 2019-02-25 2020-07-24 武汉凯德维斯生物技术有限公司 同时靶向hpv16 l1及hpv16 e5e6e7的宫颈癌疫苗及其制备方法
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
CN111153967B (zh) * 2019-12-16 2023-04-07 温州医科大学 一种对hpv16 e5蛋白特异性结合的多肽及其应用
EP4125949A4 (en) * 2020-03-23 2024-05-22 The Council of the Queensland Institute of Medical Research Compositions and methods for targeting hpv-infected cells
CN113984947B (zh) * 2020-07-27 2024-05-17 中国食品药品检定研究院 测定9价hpv疫苗中抗原蛋白含量的特异性肽段及方法
US20240285740A1 (en) 2021-05-12 2024-08-29 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
US20230105995A1 (en) * 2021-09-23 2023-04-06 Karen Anderson Multiplexed lateral flow assay for detection of hpv associated cancer
US12497569B2 (en) 2022-05-26 2025-12-16 Hydrocarbon Technology & Innovation, Llc Method and system for mixing catalyst precursor into heavy oil using a high boiling hydrocarbon diluent

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
IL63224A (en) 1980-07-17 1985-05-31 Scripps Clinic Res Synthetic peptide specific antigenic determinant and method of manufacturing antigenic materials therefrom
US4487715A (en) 1982-07-09 1984-12-11 The Regents Of The University Of California Method of conjugating oligopeptides
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
FR2591227B1 (fr) 1985-12-06 1988-11-10 Pasteur Institut Peptides capables d'inhiber les interactions entre les virus lav et les lymphocytes t4, produits qui en sont derives et leurs applications
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US5013548A (en) 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5200320A (en) 1987-12-07 1993-04-06 National Jewish Center For Immunology And Respiratory Medicine Method for identifying useful polypeptide vaccines
US5180806A (en) 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1238343B (it) 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
US5753233A (en) 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
AU1271692A (en) 1991-01-22 1992-08-27 Immune Response Corporation, The Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
DE4143467C2 (de) 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン，インコーポレイティド Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
ATE368113T1 (de) 1992-04-21 2007-08-15 Pasteur Institut Rekombinante mutanten zur induktion spezifischer immunantworten
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20020098197A1 (en) 1994-07-21 2002-07-25 Alesandro Sette Hla binding peptides and their uses
US20020168374A1 (en) 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JP3782100B2 (ja) 1992-08-07 2006-06-07 エピミューン，インコーポレイティド Ｈｌａ結合性ペプチド及びその用途
US20040096445A1 (en) 1999-06-30 2004-05-20 John Sidney Subunit vaccines with A2 supermotifs
US20020177694A1 (en) 1996-01-23 2002-11-28 Alessandro Sette Hla binding peptides and their uses
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
DE4238416A1 (de) 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US20050049197A1 (en) 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996022067A2 (en) 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US5821048B1 (en) * 1995-06-07 2000-05-23 Harvard College Methods kits and compositions for diagnosing papillomavirus infection
AUPN443995A0 (en) 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
AU738649B2 (en) 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US5783567A (en) 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
AU4078599A (en) 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
CA2370413A1 (en) 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040157273A1 (en) 2001-08-22 2004-08-12 John Sidney Subunit vaccines with a2 supermotifs

Also Published As

Publication number Publication date
CA2393960C (en) 2015-06-02
EP1246644A4 (en) 2005-05-11
US20070053922A1 (en) 2007-03-08
AU2009225354A1 (en) 2009-11-05
US20090214632A1 (en) 2009-08-27
WO2001041799A1 (en) 2001-06-14
US20130017253A1 (en) 2013-01-17
US7026443B1 (en) 2006-04-11
AU2006200654A1 (en) 2006-03-23
AU2006200654C1 (en) 2010-03-04
AU2258201A (en) 2001-06-18
JP2004512814A (ja) 2004-04-30
EP1246644A1 (en) 2002-10-09
US7572882B2 (en) 2009-08-11
AU2006200654B2 (en) 2009-07-30
AU2006200654A2 (en) 2006-03-23
CA2393960A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
EP1568373A3 (en) Inducing cellular immune responses to HER2/neu using peptide and nucleic acid compositions
WO1999033868A3 (en) Human papillomavirus vaccine
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
DK1292328T3 (da) Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse
IL150602A0 (en) Proteosome influenza vaccine
PL375306A1 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
AU4358801A (en) Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
AU4322996A (en) Variants of human papilloma virus antigens
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2002032943A3 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
Farnós et al. The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice
RU2002111554A (ru) Вакцина
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
AU5489500A (en) Isolation of a human retrovirus
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis

Legal Events

Date Code Title Description
FG Grant or registration